AUTHORS
Sikander Ailawadhi, MD, Maria Gavriatopoulou, MD2, Ioannis Ntanasis-Stathopoulos, MD3, Christian Buske, MD4, Jason Berilgen5, Kate Oliver, BS6, Jarrod Longcor, MD7, Larry D Anderson Jr, MD, PhD8
AFFILIATIONS
1 Mayo Clinic, Jacksonville, Florida, United States
2 Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece
3 Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece
4 Universitätsklinikum Ulm, Ulm, Germany
5 Woodlands Cancer Institute, The Woodlands, Texas, United States
6 Cellectar Biosciences, Florham Park, New Jersey, United States
7 Cellectar Biosciences, Florham Park, New Jersey, United States
8 UT Southwestern Medical Center, Dallas, Texas, United States
ABSTRACT
Background: Waldenström Macroglobulinemia (WM) remains incurable with current available therapeutic options. Treatment options for relapsed/refractory patients are limited, especially after a Bruton tyrosine kinase inhibitor (BTKi), underscoring the need for new agents with novel mechanisms of action and ideally fixed duration rather than continuous. Iopofosine I 131 is a novel radiopharmaceutical compound composed of a tumor-targeting phospholipid ethers (PLE) covalently bound to 131I, a beta emitting radioisotope. PLE and PLE analogs exhibit tumor-targeting properties through interaction with the altered plasma membrane in tumor cells, specifically microdomains known as lipid rafts. This selective delivery of radiation to malignant tumor cells minimizes radiation exposure to normal tissues.
As previously reported (Ailawadhi et al, ASH 2024), iopofosine I 131 has shown preliminary efficacy in heavily pre-treated WM patients [median of 4 prior therapies, range 2-15]. In 55 efficacy-evaluable patients, overall response rate (ORR) was 80% and major response rate (MRR) was 56.4%. In 39 patients exposed to a BTKi, sub-group analysis showed an ORR of 76.9% and MRR of 59%. In the safety population (n=65), Grade 3 or higher treatment-emergent adverse events (TEAEs) occurring in >10% of patients included thrombocytopenia (80%), neutropenia (69.2%), anemia (44.6%), lymphopenia (13.8%), infections (12.3%), and febrile neutropenia (10.8%). One AE-related death due to bacterial sepsis occurred. Based on these results, a Phase 3 confirmatory trial has been initiated.
Study Design: Iopofosine I 131 is being compared to rituximab-cyclophosphamide-dexamethasone (R-CD) in WM patients who have had a BTKi in a global, Phase 3, open-label, randomized trial (EU CT 2026-527281-78-00). Approximately 210 patients (+/- 10%) will be enrolled and randomized to one of two treatment arms (iopofosine I 131 or R-CD) in a 1:1 ratio.
Major inclusion criteria include patients aged ≥ 18 years, diagnosed with WM who have received at least 1 prior therapy, patients must have received a BTKi, have adequate organ and bone marrow function and ECOG performance status ≤ 2. Patients must have symptomatic disease progression requiring therapy and a measurable IgM (at least 2x the institution’s upper limit of normal).
Major exclusion criteria include Bing Neel syndrome, evidence of or suspected of having myelodysplastic syndrome, ongoing >Grade 2 toxicity from prior therapy, prior external beam radiation therapy resulting in > 20% of total bone marrow receiving > 20 Gy, and prior or concurrent malignancy. Prior to trial drug administration, patients must not have had an anti CD-20 monoclonal antibody (moAb) < 6 months, chemotherapy ≤ 4 weeks, non-anti-CD20 moAb ≤ 3 months, BTKi therapy ≤ 48 hours, or any investigational agent ≤ 2 weeks or 5 half-lives (whichever is shorter).
Iopofosine I 131 treatment consists of 2 cycles of iopofosine I 131 administered at 15 mCi/m2 on days 1 and 15 of each 92-day cycle. R-CD will be dosed as follows; dexamethasone 20 mg intravenously followed by rituximab 375 mg/m2 intravenously on day 1 and cyclophosphamide 100 mg/m2 orally bid on days 1 to 5 (total dose, 1,000 mg/m2). This regimen will be repeated every 21 days for 6 cycles.
The trial is designed to evaluate progression-free survival (PFS). The primary endpoint assesses superiority in PFS of iopofosine I 131 over R-CD; the analysis will assess the hazard ratio between the two treatment arms.
Secondary endpoints include MRR, ORR, and the proportion of patients achieving a very good partial response or complete response, as well as further evaluation of safety and tolerability. Exploratory endpoints include overall survival, duration of response, and evaluation of quality of life.
Efficacy is determined using response criteria modified from the 11th International Workshop on Waldenstrom Macroglobulinemia and will be verified by a blinded, independent efficacy response review committee. An independent data monitoring committee is overseeing safety throughout the trial.
The trial is anticipated to begin enrolling patients in Dec2026.
DISCLOSURES
Sikander Ailawadhi, MD: BMS - Research Funding; Xencor - Research Funding; Cellectar - Research Funding; Janssen - Research Funding; Ascentage Pharma Group Inc. - Research Funding; Amgen - Research Funding; Pharmacyclics - Research Funding; AbbVie - Research Funding; GSK - Research Funding; GSK - Consultancy (Includes expert testimony); Cellectar - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); Pharmacyclics - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony)